HU-x Synthetic Cannabinoids Cannabinoid Research

HU-x Synthetic Cannabinoids Research Dashboard


Primary Studies


Related Studies


Total Studies

Clinical Studies


Double-blind human trials


Clinical human trials

Pre-Clinical Studies




Animal studies


Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 75 studies associated with HU-x Synthetic Cannabinoids.

Here is a small sampling of HU-x Synthetic Cannabinoids studies by title:

Components of the HU-x Synthetic Cannabinoids Research Dashboard

  • Top medical conditions associated with HU-x Synthetic Cannabinoids
  • Proven effects in clinical trials for HU-x Synthetic Cannabinoids
  • Receptors associated with HU-x Synthetic Cannabinoids
  • Individual study details for HU-x Synthetic Cannabinoids

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - HU-x Synthetic Cannabinoids

Description of HU-x Synthetic Cannabinoids

The HU-x series are synthetic cannabinoids that carry the initials based on their place of discovery Hebrew University, Israel. For instance, HU-210 was discovered in 1988.

Other Names:

HU Family Synthetic Cannabinoids Dexanabinol (HU-211)

HU-x Synthetic Cannabinoids Properties and Effects

Binds with PPAR-? and initiates anti-inflammatory responses.

HU-x Synthetic Cannabinoids Receptor Binding

Very strong affinity at mean Ki at human CB1 ~0.25nM (100 times more potent than THC). Very strong affinity for CB2 with a mean Ki at human CB2 is ~0.40nM (86 times more potent than THC)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.